OHA Member Miami Valley Hospital Announces Enrollment of Patients for Experimental COVID-19 Treatment

Miami Valley Hospital announced Oct. 12 it is actively enrolling patients in the REGN-COV2 study, Regeneron’s investigational COVID-19 antibody treatment for patients diagnosed with COVID-19 who are hospitalized or recovering at home.

REGN-COV2 is an investigational antibody cocktail that is in clinical trials for the treatment of COVID-19. Miami Valley Hospital is the only clinical site in Ohio participating in both the hospitalized and outpatient trials. Click here to read the full press release.